Mitsubishi UFJ Trust & Banking Corp Sells 37,100 Shares of Guardant Health, Inc. (NASDAQ:GH)

Mitsubishi UFJ Trust & Banking Corp lessened its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 11.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 292,972 shares of the company’s stock after selling 37,100 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Guardant Health were worth $8,950,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Intech Investment Management LLC acquired a new stake in shares of Guardant Health during the third quarter worth $754,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Guardant Health by 6.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,986 shares of the company’s stock worth $665,000 after buying an additional 1,844 shares during the last quarter. Verition Fund Management LLC grew its position in shares of Guardant Health by 220.6% during the 3rd quarter. Verition Fund Management LLC now owns 37,641 shares of the company’s stock worth $863,000 after buying an additional 25,900 shares during the period. PDT Partners LLC increased its stake in shares of Guardant Health by 51.8% in the 3rd quarter. PDT Partners LLC now owns 219,542 shares of the company’s stock valued at $5,036,000 after acquiring an additional 74,957 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new stake in shares of Guardant Health in the 3rd quarter valued at about $21,389,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on GH. Stephens restated an “overweight” rating and set a $55.00 price objective on shares of Guardant Health in a report on Wednesday. Scotiabank boosted their price target on shares of Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Monday, February 24th. Guggenheim reaffirmed a “buy” rating and set a $56.00 price objective on shares of Guardant Health in a research note on Monday, February 24th. Raymond James reissued an “outperform” rating and issued a $59.00 target price (up from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Finally, Piper Sandler increased their price target on Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $48.95.

Guardant Health Trading Down 4.5 %

Guardant Health stock opened at $43.14 on Friday. The company has a fifty day simple moving average of $44.66 and a 200 day simple moving average of $34.30. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $50.89. The company has a market cap of $5.32 billion, a P/E ratio of -12.12 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. On average, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.